CA125 levels are significantly increased in approximately 85% of serous ovarian cancers, followed by endometrioid carcinoma, low or no expression in clear cell carcinoma, mucinous ovarian carcinoma, and specific non-epithelial tumors (such as sex cord-stromal tumor and germ cell tumor), and are affected by inflammation (38, 39). Here, MUC16 is linked to endometrioid adenocarcinoma.